ArticleEuropean journal of neurology2021
Myasthenia gravis associated with anti-MuSK antibodies developed after SARS-CoV-2 infection.
Article in European journal of neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 2 syntheses or guidelines pooled it, 57 citations in OpenAlex.
- Neurological manifestations of COVID-19: a systematic review and detailed comprehension.The International journal of neuroscience · 2023Pooled it
- Characteristics, treatment, and outcomes of Myasthenia Gravis in COVID-19 patients: A systematic review.Clinical neurology and neurosurgery · 2022Pooled it
- New-Onset Myasthenia Gravis Associated with SARS-CoV-2 Infection: A Systematic Review.Life (Basel, Switzerland) · 2026Review
- Risk of New-Onset Myasthenia Gravis Following COVID-19 Infection and Vaccination: A Population-Based Case-Control Study.European journal of neurology · 2026Article
- Association Between Post-COVID-19 Herpes Zoster Reactivation and Peripheral Nervous System Disorders: Multinational Real-World Evidence from TriNetX.International journal of medical sciences · 2026Article
- The characteristics of new-onset myasthenia gravis after COVID-19 outbreak: a cross-sectional study.Virology journal · 2025Article
- COVID-19-associated delayed-onset MuSK-positive myasthenia gravis presenting solely with respiratory failure: a case report.Frontiers in immunology · 2025Article
- The clinical risk and post-COVID-19 sequelae in patients with myasthenia gravis: a retrospective observational study.Frontiers in neurology · 2025Article
- Understanding autoimmune response after SARS-CoV-2 infection and the pathogenesis/mechanisms of long COVID.Medical review (2021) · 2024Review
- Article
- Seronegative Myasthenia Gravis: A Rare Disease Triggered by SARS-CoV-2 or a Coincidence?Cureus · 2024Article
- A Bead-Based Nonradioactive Immunoassay for Autoantibody Testing in a Mouse Model of Myasthenia Gravis.Antibodies (Basel, Switzerland) · 2024Article
- Review
- Myasthenia Gravis Triggered by a COVID-19 Infection: A Case Report and Literature Review.Cureus · 2024Article
- Clinical features of COVID-19 infection in patients with myasthenia gravis: a real-world retrospective study.Frontiers in public health · 2024Article
- Association between COVID-19 and myasthenia gravis (MG): A genetic correlation and Mendelian randomization study.Brain and behavior · 2023Article
- Neurologic and Neuromuscular Sequelae of COVID-19.Physical medicine and rehabilitation clinics of North America · 2023Review
- Autoimmune myasthenia gravis and COVID-19. A case report-based review.The Journal of international medical research · 2023Review
- Article
- EpitranscriptomicMicrobiology spectrum · 2023Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSince the onset of the novel coronavirus pandemic, several neurological complications secondary to SARS-CoV-2 infection have been reported, affecting central nervous system, peripheral nervous system and neuromuscular junction. CASE REPORT: We present the case of a 77-year-old man who developed bulbar myasthenia gravis (MG) eight weeks after SARS-CoV-2 infection. The search for serum antibodies against the acetylcholine receptor and the muscle-specific tyrosine kinase (MuSK), performed by radioimmunoassay (RIA), and the search of low-density lipoprotein receptor-related protein 4 antibodies, performed by immunohistochemistry, resulted negative, while anti-MuSK antibodies were detected by cell-based assay (CBA). The patient was treated with pyridostigmine (60 mg four times a day) with unsatisfactory clinical response, followed by immunosuppressive therapy (azathioprine 1.5 mg/kg/day) with improvement of MG symptoms after two months of treatment. DISCUSSION: Several viral diseases have been described as associated with the onset of MG, although the underlying mechanisms are not yet fully understood. Similarly, a growing number of scientific reports suggest a correlation between SARS-CoV-2 infection and autoimmune diseases. The interest of our case lies in the timing of the MG onset (after 2 months from infection), together with the unusual late onset of anti-MuSK MG. These elements suggest that coronavirus infection may act as a trigger of the disease. We confirm the importance of CBA in the serological diagnosis of RIA-negative MG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.